Palisade Bio, Inc. is a biopharmaceutical company that develops oral therapies aimed at treating major diseases resulting from damage of the gastrointestinal tract mucosal barrier. Their primary candidate is LB1148, an oral liquid formulation that obstructs digestive enzyme actions and conserves gut integrity under intestinal stress caused by reduced blood flow, infections, or surgical procedures. With headquarters based in Carlsbad, California, Palisade Bio, Inc. was established in 2005.